Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SonoVue-Enhanced Ultrasound for Focal Liver Lesions
NCT00788697Phase 3Completed
- Sponsor
- Bracco Diagnostics Inc.
- Start
- Sep 2009
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sulfur hexafluoride in liver neoplasms, sponsored by Bracco Diagnostics Inc. Primary endpoints: Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard and Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard. Started Sep 2009; status: completed.
02
Drugs
sulfur hexafluoride
03
Conditions
liver neoplasms
Beyond the preview
Go deeper on NCT00788697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00788697.